Starvation of children in Syria -sanctions and the politics of revenge
As Syria completes two years of western sanctions (2011-13), their dramatic effects on health are being highlighted with first reports of starvation deaths among children in the suburbs of Damascus (1) . Although heavy fighting has taken place in this area, experts had predicted for some time the unworkability of sanctions for regime change (2, 3) , arguing that only civilians would pay the price in a country (Syria in this case) which was once well on the way to meeting the Millennium Development Goals 4 targets on reducing child mortality (4) . In this, as in the case of other "sanctioned" countries, it is not just "civilians" but the most vulnerable among them -children, who are experiencing the tragic consequences of sanctions.
Several infants have died of hunger in the suburbs of Damascus and also in yarmouk and other pockets of the country at the epicentre of conflict.
Several children had died by mid-October (2013) and one doctor was quoted as saying to Der Spiegel (5) that dozens of infants are so weak that a mild infection will kill them. While the west remains obsessed with its own security and the need for Syria to destroy its chemical weapons so that they do not fall into the hands of the jihadists, International humanitarian law would be better served if they (the Western governments, notably the USA, UK and France) made some real effort to protect civilians by putting pressure on the Syrian government and on western-funded militias, not to continue to use civilians as a shield or a tool for vengeance. A component of point 22 states that the protocol must describe the arrangements for post-study access by the study subjects to interventions identified as beneficial in the study. Though this is very important ethically, there is a need to consider how far it is practicable. After a clinical trial has concluded, it takes from a few days to a few months to assess and reach conclusions about the beneficial effects, and it may take some time to obtain the Drugs Controller General's approval for marketing the drug. Is it possible for a company/ institutional ethics committee (IEC)/investigator/study participant to give consent for a drug, for which the analysis of the efficacy is being worked out? The participants thus have to revert to the drugs or measures they were taking earlier till the Drug Controller General grants approval. The word "arrangement" may refer to subsidised drugs or free drugs. Would this assurance of free drugs act as an inducement to participate in trials, especially those involving cancer and end-stage disease? A component of point 32, on the subject of informed consent, states that an IEC should decide on the impracticability of obtaining informed consent in the case of stored samples. As all IECs are independent, there will be various opinions on the matter.
Further, how can impracticability be decided upon? Is the difficulty in obtaining informed consent due to a large number of samples, the fact that they have come from different parts of the country, or the fact that they are taken anonymously? Are we going to permit telephonic or verbal consent if these participants are unable to come to the centre personally? Point 33 of the draft, which deals with placebo, permits their use "for compelling and scientifically sound methodological reasons…". This needs to be deleted altogether. Again, it is difficult for an IEC to determine what "compelling and scientifically sound methodological reasons" are. The same may be true of point 37, which pertains to unproven interventions. The proposed provision opens a Pandora's box in the area of stem cell studies and other studies on genetically engineered techniques. Though the draft is a reform measure aimed at promoting ethical research, it would be useful if an appendix were added to describe the practical aspects of its implementation. 3) . However, the irony is that though the state governments have agreed to these scales, apart from dearness allowance (DA) and non-practice allowance (NPA), they have left out many of the allowances paid in central medical institutes, the sum of which could well be above INR 40,000 per month.
There has been a hike in the allowances of medical teachers in central institutes (4) . However, most of the states have not yet decided on a policy for the grant of these allowances. Medical teachers in some states are given a conveyance allowance of just INR 1600 per month, which is very low compared to that given at the central level, i.e. INR 5000 per month. Recently, the Kerala government has started paying a risk allowance and a patient care allowance, which is 15% of the basic pay of
